Share on Facebook
Share on Twitter
Share on LinkedIn

As the Food and Drug Administration grapples with rising pressure to approve new medicines more quickly, a new analysis finds the agency disagreed with its expert advisory panels about one-fifth of the time. And the disagreements were more likely to occur over safety issues than over approving new products or additional uses for existing products.

Read More